The ECX™ controlled release technology is designed to ensure controlled release of the active ingredient throughout the ileum, the ascending and transverse colon.
The ECX™ technology has been successfully applied to multi-particulate dosage forms. In such systems, a capsule1 is filled with pellets made with the ECX™ controlled release technology. In the stomach, the capsule dissolves releasing the pellets. The enteric coating of the pellets, which does not dissolve until the pH in the small intestine reaches 5.5, is designed to ensure that the active ingredient in the pellet is protected from early release in the stomach. Underneath the enteric coating, the active ingredient is embedded in an EthylCellulose matriX, the ECX-layer. When each pellet reaches the small intestine, the enteric coating starts to dissolve. The ECX-layer is exposed and the active ingredient is gradually released mainly in the ileum, the ascending colon and transverse colon.
The ECX™ controlled release technology is designed to ensure a gradual, time-dependent, controlled release of the active ingredient from the pellets along the ileum, the ascending colon and transverse colon.
To learn more about the ECX™ controlled release technology, watch our video animation by clicking here.
The rights to the ECX™ technology, including the rights to the trademark, are owned by Tillotts Pharma AG in various countries except for the USA.
1 or any suitable type of final formulation